文献速递神经肿瘤

胶质母细胞瘤患者脑脊液来源细胞外囊泡中野生型EGFR扩增和EGFRvIII突变的检测

Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients.
PubMed 文献 · Neuro Oncol · 2017-01-01

多机构研究从胶质母细胞瘤患者脑脊液来源细胞外囊泡中提取RNA,检测野生型EGFR和EGFRvIII。23例组织EGFRvIII阳性患者中14例脑脊液囊泡检出EGFRvIII,48例组织阴性中仅1例检出,灵敏度61%、特异度98%。

要点

  • 脑脊液来源细胞外囊泡可检测胶质母细胞瘤的野生型EGFR RNA表达和EGFRvIII状态。
  • EGFRvIII组织阳性患者中14/23例脑脊液囊泡检出EGFRvIII,组织阴性患者中仅1/48例检出。
  • 脑脊液囊泡检测EGFRvIII的灵敏度为61%、特异度为98%,特异度高有助于确认阳性状态。

核心结论

  • 脑脊液来源细胞外囊泡所含RNA特征可反映胶质母细胞瘤野生型EGFR表达和EGFRvIII状态的分子遗传学情况。
  • 脑脊液来源细胞外囊泡诊断试验特异度高,可准确判定EGFRvIII肿瘤阳性状态,本质上是一种创伤更小的「液体活检」,可能指导胶质母细胞瘤的突变特异性治疗。

研究设计与样本

  • 多机构研究,获取接受胶质母细胞瘤切除术患者的脑脊液及配对的肿瘤组织。
  • 在肿瘤样本中测定野生型EGFR DNA拷贝数扩增以及野生型EGFR和EGFR变体III RNA表达,并在脑脊液来源细胞外囊泡中表征野生型EGFR和EGFRvIII RNA表达。

主要发现

  • EGFRvIII阳性肿瘤具有显著更高的野生型EGFR DNA扩增(P = 0.02)和RNA表达(P = 0.03)。
  • EGFRvIII阳性脑脊液来源细胞外囊泡具有显著更多的野生型EGFR RNA表达(P = 0.004)。
  • 23例组织EGFRvIII阳性胶质母细胞瘤患者中,14例脑脊液来源细胞外囊泡检出EGFRvIII;48例组织EGFRvIII阴性患者中,仅1例脑脊液来源细胞外囊泡检出EGFRvIII突变。
  • 脑脊液来源细胞外囊泡检测EGFRvIII阳性胶质母细胞瘤的灵敏度为61%、特异度为98%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: RNAs within extracellular vesicles (EVs) have potential as diagnostic biomarkers for patients with cancer and are identified in a variety of biofluids. Glioblastomas (GBMs) release EVs containing RNA into cerebrospinal fluid (CSF). Here we describe a multi-institutional study of RNA extracted from CSF-derived EVs of GBM patients to detect the presence of tumor-associated amplifications and mutations in epidermal growth factor receptor (EGFR). METHODS: CSF and matching tumor tissue were obtained from patients undergoing resection of GBMs. We determined wild-type (wt)EGFR DNA copy number amplification, as well as wtEGFR and EGFR variant (v)III RNA expression in tumor samples. We also characterized wtEGFR and EGFRvIII RNA expression in CSF-derived EVs. RESULTS: EGFRvIII-positive tumors had significantly greater wtEGFR DNA amplification (P = 0.02) and RNA expression (P = 0.03), and EGFRvIII-positive CSF-derived EVs had significantly more wtEGFR RNA expression (P = 0.004). EGFRvIII was detected in CSF-derived EVs for 14 of the 23 EGFRvIII tissue-positive GBM patients. Conversely, only one of the 48 EGFRvIII tissue-negative patients had the EGFRvIII mutation detected in their CSF-derived EVs. These results yield a sensitivity of 61% and a specificity of 98% for the utility of CSF-derived EVs to detect an EGFRvIII-positive GBM. CONCLUSION: Our results demonstrate CSF-derived EVs contain RNA signatures reflective of the underlying molecular genetic status of GBMs in terms of wtEGFR expression and EGFRvIII status. The high specificity of the CSF-derived EV diagnostic test gives us an accurate determination of positive EGFRvIII tumor status and is essentially a less invasive "liquid biopsy" that might direct mutation-specific therapies for GBMs.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Figueroa JM, Skog J, Akers J, et al. Detection of wild-type EGFR amplification and EGFRvIII mutation in CSF-derived extracellular vesicles of glioblastoma patients. Neuro Oncol. 2017. PMID: 28453784. doi:10.1093/neuonc/nox085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。